Heidi Overton's nomination to lead the Food and Drug Administration collapsed due to insufficient Senate backing, primarily driven by Republican unease surrounding her positions on vaccines, abortion, and vaping. The sudden reversal came despite expectations that the Senate health committee would advance her appointment. Separately, Merck terminated its experimental BTK inhibitor nemtabrutinib after late-stage study results indicated the oral treatment's risks likely outweighed its therapeutic benefits.
Key points
The Trump administration officially withdrew Heidi Overton's nomination to serve as FDA c…: The Trump administration officially withdrew Heidi Overton's nomination to serve as FDA commissioner because she lacked adequate Senate confirmation support.
An independent monitoring committee's evaluation prompted Merck to halt work on nemtabrut…: An independent monitoring committee's evaluation prompted Merck to halt work on nemtabrutinib after finding its benefits may not outweigh risks.
The discontinuation of nemtabrutinib terminates the development of an oral drug designed…: The discontinuation of nemtabrutinib terminates the development of an oral drug designed to inhibit the cancer-promoting BTK protein.
Sources checked by our analysis pipeline: 1
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a needed cuppa stimulation. Our choice today is ginger peach turmeric. Meanwhile, here is the latest menu of tidbits to help you on your way. We hope you conquer the world and have a wonderful day. And as always, please do stay in touch. We appreciate feedback, tips, and criticism. …
The Trump administration is pulling the nomination of Heidi Overton to lead the U.S. Food and Drug Administration over concerns that she lacked support to get confirmed by the Senate, STAT notes. The Senate’s health panel had been expected to vote on her nomination Wednesday, and the panel’s leader, Sen. Bill Cassidy (R-La.), said on Tuesday that Overton had enough support to clear his committee and win confirmation. But some GOP lawmakers had reservations about Overton, a…
Federal regulators have provided detailed explanations regarding their decision to decline approval for Summit's pharmaceutical candidate. The move delivers critical regulatory clarity for the biotechnology sector as companies monitor agency review standards. Meanwhile, leadership at the regulatory body faces ongoing uncertainty following sudden executive staffing shifts.
Healthcare teams are turning to rhythmic physical therapy to tackle motor symptoms that traditional pharmaceuticals often fail to control. Starting in February 2027, the hospital will formally integrate these music-led sessions to help individuals bypass damaged neural pathways, reduce freezing episodes, and improve coordination. The clinical initiative responds directly to a surging caseload of patients diagnosed with the progressive neurological condition.
Authorities in Greater Manchester are examining the circumstances surrounding a child who became critically ill during the afternoon at a Middleton childcare facility. Standard procedural inquiries are underway for fatalities occurring within care environments, with specialist officers deployed to assist the grieving family. Officials emphasize that the review remains preliminary as they gather information from the public.